Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1974 1
1976 3
1977 4
1978 2
1980 1
1981 1
1982 1
1983 4
1984 1
1985 3
1986 4
1987 1
1988 4
1989 4
1991 5
1992 1
1993 2
1994 4
1995 1
1996 2
1997 3
1998 4
1999 4
2000 5
2001 7
2002 9
2003 6
2004 5
2005 7
2006 4
2007 8
2008 6
2009 7
2010 7
2011 6
2012 7
2013 10
2014 4
2015 1
2016 6
2017 4
2018 5
2019 6
2020 13
2021 17
2022 13
2023 14
2024 14
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for neri, b
Search for Nerio B instead (1 results)
Emerging oral drug options for ulcerative colitis.
Salvatori S, Neri B, Marafini I, Brigida M, Monteleone G. Salvatori S, et al. Among authors: neri b. Expert Opin Emerg Drugs. 2023 Dec;28(3):191-201. doi: 10.1080/14728214.2023.2254686. Epub 2023 Sep 7. Expert Opin Emerg Drugs. 2023. PMID: 37668153 Review.
Assessing eligibility for treatment in acute myeloid leukemia in 2023.
Venditti A, Cairoli R, Caira M, Finsinger P, Finocchiaro F, Neri B, De Benedittis D, Rossi G, Ferrara F. Venditti A, et al. Among authors: neri b. Expert Rev Hematol. 2023 Mar;16(3):181-190. doi: 10.1080/17474086.2023.2185603. Epub 2023 Mar 8. Expert Rev Hematol. 2023. PMID: 36876439 Free article. Review.
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).
Noviello D, Fries W, Orlando A, Conforti FS, Bezzio C, Castiglione F, Fantini MC, Savarino EV, Festa S, Ribaldone DG, Mocci G, Grossi L, Viganò C, Imperatore N, Ceccarelli L, Gabrielli AMC, Scardino G, Saibeni S, Balestrieri P, Principi M, Campigotto M, Gravina AG, Spagnuolo R, Scaldaferri F, Neri B, Sario AD, Baldoni M, Mitri RD, Tettoni E, Calderone S, Armuzzi A, Macaluso FS, Vecchi M, Ventimiglia M, Caprioli F; VE2TO-UC study group. Noviello D, et al. Among authors: neri b. Dig Liver Dis. 2025 Jul;57(7):1419-1427. doi: 10.1016/j.dld.2025.04.025. Epub 2025 May 6. Dig Liver Dis. 2025. PMID: 40335332
Obesity and Clinical Characteristics of Inflammatory Bowel Disease.
Biancone L, Mancone R, Biancone L, Schiavone SC, Fiorillo M, Menna C, Migliozzi S, Neri B. Biancone L, et al. Among authors: neri b. Obes Facts. 2025;18(5):429-444. doi: 10.1159/000545436. Epub 2025 Mar 28. Obes Facts. 2025. PMID: 40159346 Free PMC article.
255 results